Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
February 23, 2009
- 3-Qtr Business Results: 3
February 23, 2009
- MEDICAL DEVICE NEWS IN BRIEF
February 23, 2009
- Olmetec Goes to Front on Both GP and HP Markets: Rep Track Survey
February 23, 2009
- Deposit Sales System Discussed by Council Members
February 23, 2009
- Meiji Seika to Develop Antibody Drugs for Infectious Diseases in Earnest
February 23, 2009
- 3-Track System to Be Introduced to Eliminate "Device Lag"
February 23, 2009
- MTPC Continues Cost-cutting Efforts
February 23, 2009
- The 12 Steps to Marketing Success
February 23, 2009
- Astellas to Reinforce Its Global Development System
February 23, 2009
- SELF-MEDICATION NEWS IN BRIEF
February 23, 2009
- Five Factors Responsible for Drug Lag: Mr Sekiguchi
February 23, 2009
- SSP: Hythiol-C Struggles due to Tougher Competition
February 23, 2009
- Novartis Gears Up to Enter the Top Three in Japan
February 23, 2009
- Pharmacists Are Consumers' Final Line of Defense
February 23, 2009
- GENERICS NEWS IN BRIEF
February 23, 2009
- R&D NEWS IN BRIEF
February 23, 2009
- Motesanib to Be Developed for Non-Squamous Cell Carcinoma Only
February 23, 2009
- Bayer Schering to Transfer iPS Cell-Related Rights to iZumi Bio
February 23, 2009
- Enhancing Japan's Presence in Multinational Clinical Trials
February 23, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…